- Home
- GHG vs NKTR Comparison
GHG vs NKTR Comparison
Compare GHG & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHG
- NKTR
- Stock Information
- Founded
- GHG 2004
- NKTR 1990
- Country
- GHG China
- NKTR United States
- Employees
- GHG N/A
- NKTR N/A
- Industry
- GHG Hotels/Resorts
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- GHG Consumer Discretionary
- NKTR Health Care
- Exchange
- GHG Nasdaq
- NKTR Nasdaq
- Market Cap
- GHG 255.9M
- NKTR 238.7M
- IPO Year
- GHG 2018
- NKTR 1994
- Fundamental
- Price
- GHG $3.16
- NKTR $1.36
- Analyst Decision
- GHG
- NKTR Buy
- Analyst Count
- GHG 0
- NKTR 4
- Target Price
- GHG N/A
- NKTR $2.50
- AVG Volume (30 Days)
- GHG 23.3K
- NKTR 1.1M
- Earning Date
- GHG 11-25-2024
- NKTR 11-05-2024
- Dividend Yield
- GHG 3.17%
- NKTR N/A
- EPS Growth
- GHG 69.37
- NKTR N/A
- EPS
- GHG 0.34
- NKTR N/A
- Revenue
- GHG $208,477,725.00
- NKTR $93,157,000.00
- Revenue This Year
- GHG N/A
- NKTR N/A
- Revenue Next Year
- GHG $8.78
- NKTR N/A
- P/E Ratio
- GHG $9.34
- NKTR N/A
- Revenue Growth
- GHG 48.19
- NKTR 6.17
- 52 Week Low
- GHG $2.31
- NKTR $0.41
- 52 Week High
- GHG $4.57
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- GHG 61.05
- NKTR 59.09
- Support Level
- GHG $3.01
- NKTR $1.24
- Resistance Level
- GHG $3.30
- NKTR $1.42
- Average True Range (ATR)
- GHG 0.19
- NKTR 0.09
- MACD
- GHG 0.02
- NKTR 0.01
- Stochastic Oscillator
- GHG 73.91
- NKTR 80.65
About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.